Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information

Offices

HQ
Dr Molewaterplein 50
Rotterdam, 3015, NLD

Funding

Tags

arGEN-X

To this end, arGEN-X has invented and developed a breakthrough discovery platform setting the new standard for antibody lead choice in the discovery of human antibody therapeutics.

Fuelled by the best possible natural immune responses available, our Simple Antibodyâ„¢ platform leapfrogs existing platforms in what is probably the most critical aspect of drug discovery and development: lead choice.

Recent Milestones

  • Dollar
    arGEN-X received $43.8M (€32.5M) in Series B funding. (12/1/11)
    Posted 12/1/11 at 5:11am via finsmes.com
  • Dollar
    arGEN-X received $4.5M in Series A funding. (2/11/10)
    Posted 2/15/10 at 6:25pm via onbiovc.com
  • Dollar
    arGEN-X received $13.6M in Series A funding. (9/10/09)
    Posted 9/14/09 at 6:17am via fiercebiotech.com

Videos

Screenshots

Sources

  1. arGEN-X gins $13.6M in new funds for mAB work (fiercebiotech.com) [edit]
  2. arGEN-X, BV: Series A $4.5M (onbiovc.com) [edit]
  3. arGEN-X Closes €27.5M Series B Funding Round (finsmes.com) [edit]
Edit This Page
Last Edited 11/4/13

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy